326 related articles for article (PubMed ID: 24854484)
1. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
[TBL] [Abstract][Full Text] [Related]
2. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
O'Neill KE; Senapati S; Maina I; Gracia C; Dokras A
J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
[TBL] [Abstract][Full Text] [Related]
3. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
[TBL] [Abstract][Full Text] [Related]
4. GnRH triggering may improve euploidy and live birth rate in hyper-responders: a retrospective cohort study.
Tan J; Jing C; Zhang L; Lo J; Kan A; Nakhuda G
J Assist Reprod Genet; 2020 Aug; 37(8):1939-1948. PubMed ID: 32533431
[TBL] [Abstract][Full Text] [Related]
5. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
6. Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy.
Massarotti C; Stigliani S; Gazzo I; Lambertini M; Anserini P
ESMO Open; 2023 Aug; 8(4):101597. PubMed ID: 37421801
[TBL] [Abstract][Full Text] [Related]
7. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
8. Effect of GnRH agonist alone or combined with different low-dose hCG on cumulative live birth rate for high responders in GnRH antagonist cycles: a retrospective study.
He Y; Tang Y; Chen S; Liu J; Liu H
BMC Pregnancy Childbirth; 2022 Mar; 22(1):172. PubMed ID: 35236312
[TBL] [Abstract][Full Text] [Related]
9. Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years.
Tannus S; Turki R; Cohen Y; Son WY; Shavit T; Dahan MH
Fertil Steril; 2017 Jun; 107(6):1323-1328.e2. PubMed ID: 28501366
[TBL] [Abstract][Full Text] [Related]
10. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
Griffin D; Benadiva C; Kummer N; Budinetz T; Nulsen J; Engmann L
Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
[TBL] [Abstract][Full Text] [Related]
11. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
12. Minimum dose of hCG to trigger final oocyte maturation and prevent OHSS in a long GnRHa protocol.
Chen X; Chen SL; He YX; Ye DS
J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):133-136. PubMed ID: 23392722
[TBL] [Abstract][Full Text] [Related]
13. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
14. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation.
Oktay K; Türkçüoğlu I; Rodriguez-Wallberg KA
Reprod Biomed Online; 2010 Jun; 20(6):783-8. PubMed ID: 20382080
[TBL] [Abstract][Full Text] [Related]
15. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
Owens LA; Abbara A; Lerner A; O'floinn S; Christopoulos G; Khanjani S; Islam R; Hardy K; Hanyaloglu AC; Lavery SA; Dhillo WS; Franks S
Hum Reprod; 2018 Feb; 33(2):292-302. PubMed ID: 29206944
[TBL] [Abstract][Full Text] [Related]
16. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
17. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
18. Maternal and neonatal outcomes after gonadotropin-releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization.
Budinetz TH; Mann JS; Griffin DW; Benadiva CA; Nulsen JC; Engmann LL
Fertil Steril; 2014 Sep; 102(3):753-8. PubMed ID: 24954776
[TBL] [Abstract][Full Text] [Related]
19. Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin.
Thomsen L; Humaidan P
Curr Opin Obstet Gynecol; 2015 Jun; 27(3):210-4. PubMed ID: 25811256
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]